Vicore Pharma Holding AB
F:6Y4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vicore Pharma Holding AB
F:6Y4
|
SE |
|
F
|
Federated Hermes Inc
DUS:3KC
|
US |
|
Windar Photonics PLC
F:7WP
|
DK |
|
P
|
Pfizer Inc
F:PFE
|
US |
|
Broadcom Inc
SIX:AVGO
|
US |
|
Isuzu Motors Ltd
F:ISU
|
JP |
|
Sutro Biopharma Inc
NASDAQ:STRO
|
US |
|
Mitsui O.S.K. Lines Ltd
F:MIL
|
JP |
|
H
|
HB Investment Inc
KOSDAQ:440290
|
KR |
|
W
|
Wells Fargo & Co
XMUN:NWT
|
US |
|
P
|
Pembina Pipeline Corp
F:P5P
|
CA |
|
W
|
Wells Fargo & Co
F:NWT
|
US |
Intrinsic Value
Is 6Y4 undervalued or overvalued?
See the intrinsic value estimate for 
Vicore Pharma Holding AB and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Vicore Pharma Holding AB Does
Vicore Pharma Holding AB is a Swedish drug developer focused on serious lung diseases and scarring disorders, especially idiopathic pulmonary fibrosis. It does not sell consumer products; instead, it develops prescription medicines, runs clinical studies, and works to turn its drug candidates into approved treatments. Its main scientific idea is to target the body’s angiotensin II type 2 receptor, which it believes may help slow or reduce fibrosis.
- Headquarters
- Sweden SE
- Employees
- 37
- IPO date
- Dec 10, 2015
Revenue & Expenses Breakdown
Vicore Pharma Holding AB
Earnings Waterfall
Vicore Pharma Holding AB
The intrinsic value for Vicore Pharma Holding AB (6Y4) under the Base Case is hidden EUR.
Compared with the current market price of 0.844 EUR, the stock appears hidden.
